Inventor · disambiguated record
Weiqiang Xing
Also filed as: XING WEIQIANG
10 granted patents·14 pending applications·20 citations·filing 2016–2025
84Inventor score
Top patents by PatentIndex Score
24 records- 0194US11926626B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2022·Granted Mar 12, 2024·7 cites·23 claims
- 0293US12221442B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2024·Granted Feb 11, 2025·3 cites·4 claims
- 0392US11767312B2Phthalazinone compound, and preparation method therefor and medical use thereofSHANGHAI JEMINCARE PHARMACEUTICALS CO LTD·Filed 2023·Granted Sep 26, 2023·6 cites·14 claims
- 0482US12234223B2Phthalazinone compound, and preparation method therefor and medical use thereofSHANGHAI JEMINCARE PHARMACEUTICALS CO LTD·Filed 2024·Granted Feb 25, 2025·0 cites·30 claims
- 0582US2025115606A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2024·Application pending·0 cites
- 0679US12195457B2Aromatic ring derivative as immunoregulation and preparation method and application of aromatic ring derivativeSHANGHAI JEMINCARE PHARMACEUTICALS CO LTD·Filed 2019·Granted Jan 14, 2025·2 cites·16 claims
- 0777US2025376463A1Protein degradation agent compound preparation method and applicationSHANGHAI JEMINCARE PHARMACEUTICALS CO LTD·Filed 2025·Application pending·0 cites
- 0875US2023071840A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2022·Application pending·0 cites
- 0974US2023131252A1Phthalazinone compound, and preparation method therefor and medical use thereofSHANGHAI JEMINCARE PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1071US11926643B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2022·Granted Mar 12, 2024·0 cites·20 claims
- 1170US11034696B2Compounds for inhibiting LRRK2 kinase activityGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Granted Jun 15, 2021·1 cites·18 claims
- 1267US10975081B2Substituted fused pyrazole compounds and their use as LRRK2 inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Granted Apr 13, 2021·1 cites·18 claims
- 1360US2025250269A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
- 1460US2025109148A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
- 1558US2025145596A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
- 1658US2025177362A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
- 1758US2024366639A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2022·Application pending·0 cites
- 1856US12441706B2Protein degradation agent compound preparation method and applicationSHANGHAI JEMINCARE PHARMACEUTICALS CO LTD·Filed 2020·Granted Oct 14, 2025·0 cites·31 claims
- 1955US2023391760A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2021·Application pending·0 cites
- 2053US2024083886A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2021·Application pending·0 cites
- 2153US2023322771A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2021·Application pending·0 cites
- 2249US2025188103A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
- 2339US10858367B2CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Granted Dec 8, 2020·0 cites·18 claims
- 2437US2019389850A1CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Weiqiang Xing files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →